Tesamorelin vs MGF (Mechano Growth Factor)
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Egrifta, Egrifta WR
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH 1-44) with a chemical modification that protects it from rapid breakdown. It is FDA-approved (brand name Egrifta) to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy, which makes it one of the few growth-hormone-axis peptides with a real approval behind it. Its evidence base is solid for that specific population and thinner for the general anti-aging and fat-loss uses it gets promoted for online.
Also: Mechano Growth Factor, IGF-1Ec
MGF is the name given to a splice variant of the IGF-1 gene (IGF-1Ec in humans, IGF-1Eb in rodents) that muscle switches on after loading or damage. The "MGF" sold as a peptide is usually a synthetic 24-amino-acid copy of that variant's unique tail end (the E-domain, sequence YQPPSTNKNTKSQRRKGSTFEEHK), often with a modified C-terminus. It got famous through early lab work from Geoffrey Goldspink's group suggesting it kicks muscle stem cells into action. The honest picture is messier: a careful 2014 pharma replication found no effect on muscle cells at all, nobody has shown the free peptide actually exists in the body, and there are zero human trials.
Key Comparison Insights
- Tesamorelin is FDA approved, while MGF (Mechano Growth Factor) remains in research stages.
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- Tesamorelin has stronger research evidence (FDA Approved) compared to MGF (Mechano Growth Factor) (Preclinical).
Detailed Comparison
| Attribute | Tesamorelin | MGF (Mechano Growth Factor) |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Tesamorelin tells the pituitary gland to release the body's own growth hormone by acting on GHRH receptors, rather than injecting growth hormone directly. Because it works upstream, it produces a more natural, pulsing pattern of growth-hormone release. The molecule is GHRH 1-44 with a trans-3-hexenoic acid group added to the N-terminus, and that modification slows enzymatic degradation so the signal lasts longer than native GHRH. The downstream rise in growth hormone and IGF-1 is what drives the reduction in visceral fat seen in trials. This is a genuinely upstream, receptor-based mechanism, well characterized in human studies. | The idea goes like this. When muscle is stretched or injured, the IGF-1 gene is spliced differently, producing a version with a different C-terminal E-domain. Researchers proposed that this E-domain gets cut off and acts on its own, pushing satellite cells (muscle stem cells) to multiply before mature IGF-1 tells them to fuse and build new fibers. Several studies reported that the E-peptide works without the classic IGF-1 receptor, and in heart cells it was reported to enter the cell, travel to the nucleus, and block the mitochondrial apoptosis pathway. The problem is that nobody has identified MGF's receptor, a 2010 Endocrinology review pointed out that no matching peptide has ever been isolated from cells, tissue or blood, and a 2014 study from Novartis and another drug company could not reproduce the core muscle-cell effects. So the mechanism is a hypothesis built on synthetic-peptide experiments, not established biology. |
| Common Dosing | 2 mg daily (F8: 1.28 mg daily) Once daily | No established human dose Not established |
| Administration | Subcutaneous injection | Local injection or infusion into tissue in animal studies; research-market products are injected |
| Typical Duration | Indefinite for approved indication | Single treatments or days to weeks in animal models; no human protocols exist |
| Best Time to Take | Before bed (fasted) | Not established |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The approval rests on real randomized, placebo-controlled human trials. The pivotal study by Falutz and colleagues (New England Journal of Medicine, 2007) showed that six months of tesamorelin selectively reduced visceral abdominal fat in HIV patients while improving lipid profiles, without meaningful harm to blood sugar control. Later randomized work (including a JAMA-published trial led by Stanley) confirmed reductions in visceral fat and liver fat. A small placebo-controlled study in non-HIV adults with abdominal obesity also found a meaningful visceral fat reduction over 26 weeks, hinting at broader potential, though that is far less established than the HIV indication. Side effects can include joint pain, swelling, and increases in IGF-1, and growth-hormone-axis drugs warrant caution in people with cancer history or uncontrolled diabetes. In short: well proven for HIV-associated visceral fat, promising but not approved for general use. | The supportive work is real but almost all in cells and animals. Yang and Goldspink (FEBS Letters, 2002) reported that the E-domain increased myoblast proliferation and delayed differentiation. Kandalla and colleagues (2011) reported it extended the proliferative lifespan of human muscle precursor cells from young donors, but not from old donors. In sheep with induced heart attacks, local MGF E-domain preserved cardiac function and cut compromised heart muscle by about 35% (Carpenter, 2008), and similar heart-protection results came from mouse studies. A gerbil stroke model showed strong neuroprotection (Dluzniewska, 2005). Then the counterpoint: Fornaro and colleagues (Am J Physiol Endocrinol Metab, 2014) tested MGF up to 500 ng/ml on mouse and human muscle cells and primary muscle stem cells and saw no effect on proliferation or differentiation, while real IGF-1 worked fine. An accompanying editorial was titled "The Fall of Mechanogrowth Factor?". In humans, the only solid data is about gene expression: heavy leg extensions raised MGF mRNA in young men but not in older men (Hameed, 2003). There are no human dosing studies and no clinical trials. One more flag: MGF E-peptide drove growth of prostate cancer cells in a lab study, and MGF was found overexpressed in prostate cancer tissue (Armakolas, 2010). |
Frequently Asked Questions: Tesamorelin vs MGF (Mechano Growth Factor)
What is the difference between Tesamorelin and MGF (Mechano Growth Factor)?
Tesamorelin is a growth hormone peptide that tesamorelin is a stabilized analog of growth-hormone-releasing hormone (ghrh 1-44) with a chemical modification that protects it from rapid breakdown. it is fda-approved (brand name egrifta) to reduce excess visceral abdominal fat in people with hiv-associated lipodystrophy, which makes it one of the few growth-hormone-axis peptides with a real approval behind it. its evidence base is solid for that specific population and thinner for the general anti-aging and fat-loss uses it gets promoted for online. MGF (Mechano Growth Factor) is a growth hormone peptide that mgf is the name given to a splice variant of the igf-1 gene (igf-1ec in humans, igf-1eb in rodents) that muscle switches on after loading or damage. the "mgf" sold as a peptide is usually a synthetic 24-amino-acid copy of that variant's unique tail end (the e-domain, sequence yqppstnkntksqrrkgstfeehk), often with a modified c-terminus. it got famous through early lab work from geoffrey goldspink's group suggesting it kicks muscle stem cells into action. the honest picture is messier: a careful 2014 pharma replication found no effect on muscle cells at all, nobody has shown the free peptide actually exists in the body, and there are zero human trials. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Tesamorelin or MGF (Mechano Growth Factor)?
Neither is universally "better" - the choice depends on your specific goals. Tesamorelin is typically used for growth hormone purposes, while MGF (Mechano Growth Factor) is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Tesamorelin and MGF (Mechano Growth Factor) be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Tesamorelin and MGF (Mechano Growth Factor) together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.